SOUTH SAN FRANCISCO, CA, USA I 06, 2025 I Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 ...
A new coverage determination will prevent Medicare patients with certain cancers from accessing genetic testing, a move that advocates and testing companies say will severely limit early interventions ...